Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:

NCT ID: NCT05318937 Completed - Parkinson Disease Clinical Trials

A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

Start date: July 6, 2022
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Parkinson's disease mild cognitive impairment (PD-MCI).

NCT ID: NCT05318703 Completed - Clinical trials for Mild Cognitive Impairment

Virtual Exercise For Older Adults With Mild Cognitive Impairment

Start date: January 20, 2021
Phase: N/A
Study type: Interventional

This project is designed to develop and evaluate an Internet-based exercise intervention (tai ji quan Moving to Improve Brain Health) using real-time videoconferencing for older adults with mild cognitive impairment (MCI).

NCT ID: NCT05311852 Completed - COVID-19 Clinical Trials

Effects of PEA-LUT on Frontal Lobe Functions and GABAergic Transmission in Long-Covid Patients

PL-PC19
Start date: August 16, 2021
Phase: N/A
Study type: Interventional

The study explore the efficacy of PEA-LUT in patients suffering from neurological symptoms of Long-Covid

NCT ID: NCT05308004 Completed - Clinical trials for Cognitive Impairment

Palliative Care for Persons With ADRD and CI in SNF

Start date: June 15, 2022
Phase: N/A
Study type: Interventional

Alzheimer's disease and related dementias (ADRD) are serious, life limiting illnesses with no known cure. Dementia is the fifth-leading cause of death in older adults and the majority of people with advanced dementia die in nursing homes (NHs). Miller et al reported that 40% of U.S. NH residents dying with advanced dementia received Skilled Nursing Facility (SNF) care in the last 90 days of life, and receipt of this care was associated significantly with poorer end-of-life outcomes, including a higher risk of dying in a hospital, compared to decedents with no SNF care. SNF care is a Medicare post-acute rehabilitation service delivered in NHs focused on intense rehabilitation and/or aggressive, disease-modifying therapies. Regardless of life expectancy, use of SNF care precludes access to Hospice services. Palliative care (PC) offers an evidence-based alternative.

NCT ID: NCT05298540 Completed - Clinical trials for Postoperative Cognitive Dysfunction

Feasibility and Acceptability of Home-based Computerised Cognitive Training After Cardiac Surgery

FACCT
Start date: August 1, 2022
Phase: N/A
Study type: Interventional

The aims of this study are to (1) evaluate the feasibility and acceptability of a home-based computerised cognitive training programme in the postoperative cardiac surgical population, and (2) estimate measures of precision about the mean and variance of cognitive outcome to inform sample size calculations for a subsequent efficacy study.

NCT ID: NCT05296239 Completed - Quality of Life Clinical Trials

SimpleC Wellness Platform With Social Robot Interaction

Start date: February 3, 2022
Phase: N/A
Study type: Interventional

This implementation study will be conducted to test a Socially-Assistive Robot (SAR) system for residents in an Assisted Living environment. The goal of the SAR system is to enhance social engagement and connectedness. The system engages residents via robot-facilitated activities such as trivia and reminder and is integrated with the SimpleC Wellness Platform.

NCT ID: NCT05295966 Completed - Dementia Clinical Trials

Multisensory Physical Exercises in People With Cognitive Impairment

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The main objective of the study is to evaluate the efficacy of a combined training program of physical exercise and multisensory stimulation (Physiocognitive Integration) in people with mild/moderate cognitive impairment.

NCT ID: NCT05293561 Completed - Clinical trials for Cognitive Impairment

Cognitive Impact in Patients With COVID-19 Infection

Start date: June 1, 2021
Phase:
Study type: Observational

SARS-COV-2 (severe acute respiratory syndrome- corona virus - 2) infection reframed medical knowledge in many aspects, yet there is still a lot to be discovered. Coronavirus disease 19 (COVID-19) can cause neuropsychiatric, psychological and psychosocial impairments. Literature regarding cognitive impact of COVID-19 is still limited. Objective: evaluation of cognitive function, anxiety and depression among patients with Coronavirus disease 19.

NCT ID: NCT05292378 Completed - Healthy Clinical Trials

Carbon Dioxide (CO2) and Cognitive Impairment

Start date: July 14, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to better understand the biological mechanisms of carbon dioxide (CO2)-induced cognitive impairments.

NCT ID: NCT05286697 Completed - Clinical trials for Postoperative Cognitive Dysfunction

The Effect of Optic Nerve Diameter on Postoperative Cognitive Function in Laparoscopic Hysterectomy

Start date: March 15, 2022
Phase: N/A
Study type: Interventional

Prospective study, 40 patients ASA 2-3, 30-75 years old who were planned for laparoscopic hysterectomy operation will be included.One day before the operation and postoperative 1.3.7. A mini mental assessment test will be performed on these days.Standard monitoring and Near-Infrared Spectroscopy monitoring to measure cerebral oxygen saturation will be performed on the patients.NIRS sensors will be placed on the right and left sides of the forehead, 2 cm above the eyebrow, before induction of anesthesia. Before the induction of anesthesia, the measurement will begin and the FiO2 (fraction of inspiration oxygen) will be kept at 60%.General anesthesia induction will be made with propofol 2mg/kg, remifentanil 0.5 µg/kg and rocuronium 0.6mg/kg, and maintenance will be provided with 2% sevoflurane.The patient will be intubated and ventilation support will be provided so that the tidal volume is 6-8 ml/kg and the end tidal CO2 is 30-40 mmHg. PEEP (Positive end expiratory pressure) will not be applied to any patient. Intra-abdominal pressure will be maintained at 15 mmHg. All patients will be given 1gr paracetamol and 100mg tramadol for postoperative analgesia.During the measurement of optic nerve diameter, a layer of sterile water-soluble gel will be applied on the closed eyelid with a linear 10-5 MHz ultrasound probe. In our study, ONSDs of all patients will be measured by the same experienced anesthetist. Measurements will be made at 5 different times. 5 minutes after induction of anesthesia in the supine position (T0), 5 minutes after the onset of pneumoperitoneum (T1), 5 minutes after the upright trendelenburg position (T2), at the 2nd hour of the trendelenburg position (T3) and 5 minutes after returning to the supine position at the end of the surgery (T4) .ONSD measurements of the patients measured at 5 different times, peroperative NIRS values, peroperative SpO2, mean blood pressure, peak heart rate, anesthesia time, surgery time, time to stay in the trendelenburg position, partial oxygen saturation (PaO2), PCO2, end-tidal carbon dioxide (ETCO2) and peak airway pressure (pPEAK) will be recorded.